人民网北京12月19日电 （记者乔业琼）"近视手术做完就彻底摆脱近视，度数不会反弹"？市面上 有一些声称能防控近视、改善视力的"近视防控贴""护眼仪"等产品真的有用吗？在国家卫生健康委今日 召开的新闻发布会上，复旦大学附属眼耳鼻喉科医院主任医师周行涛进行了解答。 周行涛表示，近视手术做完就彻底摆脱近视，这种认识是不全面的。因为近视本身是不能治愈，做 完近视手术后，如果没有注意保护眼睛的话，会发生新的近视。当然，近视手术确实可以摆脱对眼镜的 依赖，因为现在角膜激光手术，比如全飞秒、半飞秒，新的Smile Pro，还有眼内镜晶体手术，比如 ICL、V4C或者V5，这类晶体的手术，确实能够让眼睛摆脱眼镜的困扰，而且能够看得清楚。但是在矫 正视力的同时，提倡术后长期关注自己的视力保健，如果长时间没有节制用眼，或者揉眼等不恰当的行 为方式，仍然会让视力受到影响。 在平时，应该如何做才能保护好视力？周行涛表示，最重要的还是规律作息，避免过度用眼，尤其 是避免长时间对着电子屏幕。推荐"20—20"方法，即看电子屏幕时，每20分钟至少休息20秒，当然最好 2分钟。或者看看远处，也就是5米远的距离，可以有效起到让眼睛放松、保护 ...

中新网12月19日电 国家卫生健康委19日召开新闻发布会，介绍时令节气与健康(冬至)有关情况。会上， 有记者提问，市面上有一些声称能防控近视、改善视力的"近视防控贴""护眼仪"等产品，请问这些产品 真的有用吗？ 周行涛表示，对近视防控，应该优先选择经过验证的方法。第一是生活行为方式，每天至少2小时的户 外活动，如果有一些孩子确实很难做到，至少一小时的户外时间是有的，这是一个非常有效的近视防控 的方法。第二是光学手段，现在包括OK镜、框架眼镜当中一部分功能镜，但要在医生的指导下使用。 第三是药物，包括低浓度阿托品等，这些需要在医嘱下使用。 对此，复旦大学附属眼耳鼻喉科医院主任医师周行涛特别强调，这些产品是否有效，当下暂时还没有医 学的证据，所以这些是不推荐的。他表示，选择这些所谓的防控措施(产品)，是忽视了近视目前还不能 治愈的事实。近视发生以后，比如眼轴延长以后，就已经近视了，目前还没有有效的逆转方法。 ...

Core Insights - The rapid increase in myopia among adolescents is a significant concern, with various preventive measures recommended by experts [2][3] - Emphasis on controlling screen time and promoting outdoor activities as effective strategies to mitigate myopia risk [2][3] Group 1: Preventive Measures - Controlling eye usage time, especially for prolonged and close-range activities, is crucial for myopia prevention [2] - Increasing outdoor activities is highlighted as one of the most economical and effective measures for eye relaxation and myopia prevention [2] - Developing good eye habits, including proper posture and reading techniques, is essential for controlling myopia [2] Group 2: Lifestyle Recommendations - A balanced diet, sufficient sleep, and regular eye examinations are also important components of myopia prevention [2] - Monitoring close-range and prolonged eye usage, along with scientific eye care practices, is key to managing myopia risk [2] Group 3: Electronic Device Usage - Despite the presence of eye protection features in modern electronic devices, they do not completely alleviate the strain on eyes or the risk of myopia [3] - Strict control of electronic device usage time is recommended for young children, with specific limits set for different age groups [3] - Comprehensive preventive measures, including the use of OK lenses, low-concentration atropine eye drops, and functional glasses, can help manage myopia progression [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to experience rapid growth in 2025, particularly with the anticipated increase in sales of low-concentration atropine [3][4] - In 2024, the company reported a revenue of 1.943 billion yuan, representing a year-on-year increase of 32.42%, and a net profit attributable to shareholders of 338 million yuan, up 40.84% [3][4] - The company is positioned as a leader in the myopia prevention medication sector, with a strong focus on the promotion of its core product, low-concentration atropine [3][4] Financial Summary - The company's revenue is projected to grow from 1.943 billion yuan in 2024 to 2.948 billion yuan in 2025, reflecting a year-on-year growth rate of 51.7% [6] - The net profit attributable to shareholders is expected to increase significantly from 338 million yuan in 2024 to 688 million yuan in 2025, marking a growth of 103.6% [6] - The gross margin is forecasted to improve from 78.3% in 2024 to 80.6% in 2025, while the net margin is expected to rise from 17.4% to 23.3% during the same period [6] Product Development - The company has developed a series of ophthalmic products, including the first approved cyclosporine eye drops for dry eye syndrome in China, which generated sales of 298 million yuan in 2023 [4] - The approval of sulfate atropine eye drops in March 2024 is expected to enhance the company's product lineup and meet the growing demand for myopia treatment among children and adolescents [4] - The revenue from eye drops is projected to reach 1.366 billion yuan in 2024, with a remarkable growth rate of 106.08% [4]